Clinical Trial Update: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RC48-ADC in combination with AK104 for perioperative treatment of muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Muscle Invasive Bladder Carcinoma | Phase 2 | Status: UNKNOWN